Schizophrenia/Psychosis

To image or not to image? Researchers performed a systematic review and meta-analysis of neuroradiological abnormalities in first-episode psychosis.

These results were instrumental in securing the FDA approval of the drug for the treatment of schizophrenia in adults in April 2023.

From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.

The trial’s results showed statistically significant reductions in all major symptom domains and secondary endpoints.

The experts weighed in on a wide variety of psychiatric issues for the October 2023 issue of Psychiatric Times.

From deep brain stimulation for treatment-resistant schizophrenia to a look at the potential trajectory of artificial intelligence in psychiatry and medicine, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of October.

Anorexia nervosa may be underdiagnosed in patients with schizophrenia due to difficulty in distinguishing the two comorbid conditions.

Due to ethical, knowledge, cost, and acceptability issues, deep brain stimulation is underutilized in disease states like treatment-resistant schizophrenia.

Here’s why you should initiate clozapine sooner in patients with treatment-resistant schizophrenia.

From long-acting injectable antipsychotics for managing schizophrenia to mental health responses to the recent conflict in Israel, here are highlights from the week in Psychiatric Times.

What is new in research on schizophrenia?

Sanjai Rao, MD, shared best practices for utilizing long-acting injectable antipsychotics at the 2023 Psychiatric Times World CME Conference.

Explore the relationship between cannabis use and psychosis.

Don't miss updates on schizophrenia at our conference, beginning at 3:10PM EST!

The NCE’s developer has announced that it is now initiating phase 3 studies.

This study is the first to assess the efficacy of this drug combination in a real-world setting.

What is the risk of diabetes, hypertension, or hyperlipidemia with antipsychotic polypharmacy in patients with schizophrenia? Researchers investigated these associations in a population-based prospective cohort study.

Get ready for our upcoming virtual, interactive conference with some highlights from 2022.

The experts weighed in on a wide variety of psychiatric issues for the September 2023 issue of Psychiatric Times.

From connections between cannabis use and schizophrenia to some non-psychiatric medications that may worsen symptoms of major depression, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of September.

The treatment, if approved, “will represent the first novel pharmacological approach to treating schizophrenia in several decades and provide a new treatment option for patients and their physicians.”

A look at the association between cannabis use and schizophrenia, as well as the need for comprehensive public health policies and education.

Here’s what the historic case of the Genain quadruplets reveals about some deeper, uncomfortable truths about American society.

The presentation of schizophrenia differs significantly between men and women. Here's what you need to know.

What is new in research on psychiatric care for Latinx patient populations?

An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

Christoph Correll, MD, shares more on paliperidone palmitate 6-month for the treatment of schizophrenia.

These 3 posters covered the efficacy and safety of paliperidone palmitate in patients with schizophrenia.